The short version
- Why people research itLibido, hormonal signaling and reproductive / sexual function.
- What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
- What to watchSexual function changes, breast tenderness or mood shifts.
How RU58841 works
Non-steroidal androgen receptor antagonist designed for topical use — it blocks DHT AT the follicle rather than lowering it systemically, which is the entire appeal versus finasteride.
Start with what this molecule is, because the structure explains both the design intent and why the design intent is only half-proven. RU58841 is 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile, C17H18F3N3O3, molecular weight 369.34, computed XLogP 2.1 National Center for Biotechnology Information 2026.
The first half is a 4-cyano-3-(trifluoromethyl)phenyl group fused to a dimethylhydantoin. That is not a novel pharmacophore — it is the same benzonitrile-hydantoin architecture that defines the non-steroidal antiandrogen class, and it is why RU58841 is an androgen receptor antagonist and not a 5-alpha-reductase inhibitor. This distinction is the single most important thing on the page.
- Topical
On the goal map: Hair — follicle biology & the androgen problem (Skin, hair & aesthetics)
Research on RU588415 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
No completed human trial
Correlative data
Developed for androgenetic alopecia and abandoned before human trials — not for a published safety finding, but the program ended and no data was released, which is itself worth weighing.
Community use is substantial and long-running, with reports of efficacy comparable to or better than topical finasteride and, in some users, systemic effects that the 'non-systemic' framing does not predict.
How the mechanism reads
A non-steroidal androgen receptor antagonist designed for topical use — it blocks the receptor locally rather than reducing DHT, which is a different mechanism from finasteride entirely.
MechanisticThe design intent was local action with rapid systemic breakdown. And reports of systemic androgen blockade suggest it may not always.
Mechanistic
Sources
- Battmann T, Bonfils A, Branche C. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism.. J Steroid Biochem Mol Biol 1994 · PMID 8136306
- Matias JR, Gaillard M. Local inhibition of sebaceous gland growth by topically applied RU 58841.. Ann N Y Acad Sci 1995 · PMID 7625751
- De Brouwer B, Tételin C, Leroy T. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice.. Br J Dermatol 1997 · PMID 9415227
- Pan HJ, Wilding G, Uno H. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques.. Endocrine 1998 · PMID 9798729
- National Center for Biotechnology Information. PubChem Compound Summary for CID 132981, RU-58841.. PubChem, retrieved 2026
RU58841 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Pregnancy, or contact with a pregnant partner's skin: an androgen blocker can feminize a male fetus.
- Under 18: blocking androgen receptors during puberty is unstudied.
- Planning conception soon: systemic absorption, if any, could change sperm output.
- Scalp dermatitis or open skin, which raises absorption.
- Hormone-sensitive conditions you manage with androgens.
What’s expected
- If it works, less DHT-driven shrinking of follicles at the scalp itself.
- Scalp dryness or mild irritation.
- Possible dip in libido if enough reaches the bloodstream; no human data measure this.
- A rise in LH is the signal that blockade is systemic.
Watch for
- Sexual function changes, breast tenderness or mood shifts.
- Scalp rash or weeping.
- Reduced facial or body hair growth.
- Testicular ache or low semen volume.
Labs that tell you it’s working
- Total & Free Testosterone (ECLIA/Direct)
- LH & FSH
- Estradiol, Sensitive [LC/MS-MS]
- SHBG (Sex Hormone-Binding Globulin)
Non-steroidal androgen receptor antagonist meant to act at the follicle; no human trial exists, so systemic leakage is unmeasured. PMID 9415227 PMID 9798729
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “Low T? Rule Out the Reversible Causes First” panel, explained
RU58841 FAQ4 common questions
- Is RU58841 approved for human use?
- No. RU58841 is a research compound. No completed randomized human trial has given it yet.
- What is RU58841 researched for?
- Libido, hormonal signaling and reproductive / sexual function.
- Which labs show whether it's doing anything?
- Total & Free Testosterone; LH & FSH; Estradiol, Sensitive [LC/MS-MS]; SHBG: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for RU58841: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



